203 related articles for article (PubMed ID: 35801202)
1. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study.
Zhang W; Li X; Chen B; Zhang J; Torres-Culala KMT; Zhou C
Front Med (Lausanne); 2022; 9():891434. PubMed ID: 35801202
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients.
Cranwell W; Meah N; Wall D; Bevin B; Laita B; Sinclair RD
Australas J Dermatol; 2024 Jun; ():. PubMed ID: 38831704
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
5. A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis.
Sharath S; Sardana K; Khurana A
Indian Dermatol Online J; 2024; 15(1):49-54. PubMed ID: 38282998
[TBL] [Abstract][Full Text] [Related]
6. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
Kibbie J; Kines K; Norris D; Dunnick CA
Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.
Shivanna CB; Shenoy C; Priya RA
Int J Trichology; 2018; 10(3):103-107. PubMed ID: 30034188
[TBL] [Abstract][Full Text] [Related]
8. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of tofacitinib in 97 alopecia areata patients.
Nasimi M; Abedini R; Ghandi N; Teymourpour A; Babaie H
J Cosmet Dermatol; 2024 May; ():. PubMed ID: 38736269
[TBL] [Abstract][Full Text] [Related]
10. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study.
Jerjen R; Meah N; Trindade de Carvalho L; Wall D; Eisman S; Sinclair R
Pediatr Dermatol; 2021 Jan; 38(1):103-108. PubMed ID: 33099833
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Benton S; Farah R; Freese R; Hordinsky M
Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
[TBL] [Abstract][Full Text] [Related]
12. Experience with oral tofacitinib in severe alopecia areata with different clinical responses.
Dincer Rota D; Emeksiz MAC; Erdogan FG; Yildirim D
J Cosmet Dermatol; 2021 Sep; 20(9):3026-3033. PubMed ID: 33533091
[TBL] [Abstract][Full Text] [Related]
13. Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population.
AlMarzoug A; AlOrainy M; AlTawil L; AlHayaza G; AlAnazi R; AlIssa A; AlSheikh A; AlKhalifah A; AlHarithy R
Int J Dermatol; 2022 Jul; 61(7):886-894. PubMed ID: 34716573
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review.
Huang J; Li T; Tan Z; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Sep; 103():adv13418. PubMed ID: 37731213
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib as a treatment of alopecia areata in adolescents.
Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
[TBL] [Abstract][Full Text] [Related]
17. Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy.
Perche P; Purvis C; Pichardo R
J Drugs Dermatol; 2022 Dec; 21(12):1366-1368. PubMed ID: 36468955
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.
Huang J; Qian P; Tang Y; Li J; Liu F; Shi W
Acta Derm Venereol; 2023 Dec; 103():adv12425. PubMed ID: 38112208
[TBL] [Abstract][Full Text] [Related]
19. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.
Kołcz K; Żychowska M; Sawińska E; Reich A
Dermatol Ther (Heidelb); 2023 Mar; 13(3):843-856. PubMed ID: 36639612
[TBL] [Abstract][Full Text] [Related]
20. Systematic review - alopecia areata and tofacitinib in paediatric patients.
Bandeira A; Albino-Teixeira A; Magina S
Cutan Ocul Toxicol; 2022 Jun; 41(2):194-201. PubMed ID: 35687530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]